Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
PIAI^ Prime Impact Acquisition I
CGEN Compugen Ltd
FPAY FlexShopper Inc
IOACW Innovative International Acquisition Equity Warrants Exp 26th Oct 2026 *W EXP 10/26/2026
FUSN Fusion Pharmaceuticals Inc
COUR Coursera Inc
SIMO Silicon Motion Technology Corp
CGNX Cognex Corp
SNTG Sentage Holdings Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Closing Price
$277.42
Day's Change
16.11 (6.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
278.25
Day's Low
256.64
Volume
(Average)
Volume:
1,303,903

10-day average volume:
1,249,254
1,303,903

Karuna Therapeutics to Present at Upcoming Investor Conferences

6:30 am ET June 6, 2022 (BusinessWire) Print

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that senior management will present at the following upcoming investor conferences:

William Blair 42nd Annual Growth Stock Conference Date: Wednesday, June 8, 2022 Time: 5:00 p.m. ET

Goldman Sachs 43rd Annual Global Healthcare Conference Date: Tuesday, June 14, 2022 Time: 5:00 p.m. ET

A live webcast of the presentations will be available on the Investor Relations page of Karuna's website at investors.karunatx.com. A replay of the webcasts will also be archived for up to 30 days on Karuna's website following the conference.

About Karuna Therapeutics

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples' lives. For more information, please visit www.karunatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005094/en/

SOURCE: Karuna Therapeutics, Inc.

Investor: 
Alexis Smith
518-338-8990
asmith@karunatx.com 

Media: 
Lauren Sneider
917-886-0247
lsneider@karunatx.com
comtex tracking

COMTEX_408273337/1006/2022-06-06T06:30:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.